PT - JOURNAL ARTICLE AU - Wang, Hao AU - Wu, Qi AU - Yang, Lang AU - Chen, Long AU - Liu, Wen-Zhong AU - Xu, Jing-Song TI - Application of AMR in evaluating microvascular dysfunction after ST-segment elevation myocardial infarction AID - 10.1101/2023.05.11.23289795 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.11.23289795 4099 - http://medrxiv.org/content/early/2023/05/14/2023.05.11.23289795.short 4100 - http://medrxiv.org/content/early/2023/05/14/2023.05.11.23289795.full AB - BACKGROUND Quantitative flow ratio (QFR) is a new method to estimate fractional flow reserve based on three-dimensional quantitative coronary angiography, from which angiography-derived microcirculatory resistance (AMR) without guidewires and adenosine is derived as an indicator of microvascular dysfunction. This study aimed to assess coronary microvascular dysfunction (CMD) in patients with ST-segment elevation myocardial infarction (STEMI) by AMR.METHODS A retrospective collection of 506 STEMI patients who successfully underwent percutaneous coronary intervention (PCI) from June 1, 2020, to September 28, 2021, was divided into the CMD group and the non-CMD group based on the value of AMR, while we used propensity score matching (PSM) to adjust for baseline characteristics. The primary endpoint was the 1-year rate of major adverse cardiac events (MACE), a composite of death from any cause, myocardial infarction, readmission for heart failure, or ischemia-driven revascularization.RESULTS The 1-year rate of MACE in CMD group was higher than that in the non-CMD group (post-match HR 1.954, 95% CI:1.025 to 3.726; 14.1% vs. 7.3%, P=0.042); Subgroup analysis showed that the readmission rate of heart failure (HF) was higher in the CMD group than in the non-CMD group (post-match HR 5.082, 95% CI:1.471 to 17.554; 7.9% vs. 1.6%. P=0.010). The results of survival analysis suggested that AMR ≥250mmHg*s/m was an independent predictor of the primary endpoint in STEMI patients (post-match adjusted HR 2.265, 95% CI: 1.136 to 4.515, P = 0.020). CONCLUSION: As an indicator of microvascular dysfunction, AMR can be a viable alternative to invasive wire-based IMR in STEMI patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the Second Affiliated Hospital of Nanchang University(Nanchang, China)gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors